Efficacy and safety of novel oral anticoagulants versus low molecular weight heparin in cancer patients with venous thromboembolism: A systematic review and meta-analysis.

[1]  Agnes Y. Y. Lee,et al.  Anticoagulant Therapy for Venous Thromboembolism in Cancer. , 2020, The New England journal of medicine.

[2]  A. Torbicki,et al.  Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. , 2020, The New England journal of medicine.

[3]  M. Humbert,et al.  2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): supplementary data , 2019 .

[4]  Natalie S Blencowe,et al.  RoB 2: a revised tool for assessing risk of bias in randomised trials , 2019, BMJ.

[5]  K. Porter,et al.  A single center retrospective cohort study comparing low-molecular-weight heparins to direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer – A real world experience , 2019, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[6]  M. Murad,et al.  Direct Oral Factor Xa Inhibitors for the Treatment of Acute Cancer-Associated Venous Thromboembolism: A Systematic Review and Network Meta-analysis. , 2019, Mayo Clinic proceedings.

[7]  C. Combescure,et al.  Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis , 2019, PloS one.

[8]  Joshua D. Brown,et al.  Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis. , 2019, The Lancet. Haematology.

[9]  G. Lyman,et al.  Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. , 2019, Thrombosis research.

[10]  A. H. Mohammed,et al.  Correction to: Direct oral anticoagulants for the treatment of venous thromboembolism in patients with active malignancy: a systematic review and meta-analysis , 2018, Journal of Thrombosis and Thrombolysis.

[11]  H. Badreldin,et al.  Direct oral anticoagulants for the treatment of venous thromboembolism in patients with active malignancy: a systematic review and meta-analysis , 2018, Journal of Thrombosis and Thrombolysis.

[12]  G. Lyman,et al.  Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Khorana,et al.  Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer , 2018, American journal of hematology.

[14]  G. Raskob,et al.  Edoxaban for the Treatment of Cancer‐Associated Venous Thromboembolism , 2017, The New England journal of medicine.

[15]  C. Loprinzi,et al.  Apixaban and dalteparin in active malignancy associated venous thromboembolism , 2017, Thrombosis and Haemostasis.

[16]  A. Khorana,et al.  Current practice patterns and patient persistence with anticoagulant treatments for cancer‐associated thrombosis , 2017, Research and practice in thrombosis and haemostasis.

[17]  W. Leung,et al.  Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management , 2017, World journal of gastroenterology.

[18]  N. Brunetti,et al.  Direct oral anti-coagulants compared with vitamin-K inhibitors and low-molecular-weight-heparin for the prevention of venous thromboembolism in patients with cancer: A meta-analysis study. , 2017, International journal of cardiology.

[19]  S. Schulman,et al.  Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH , 2015, Journal of thrombosis and haemostasis : JTH.

[20]  L. Robertson,et al.  Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis. , 2015, The Cochrane database of systematic reviews.

[21]  F. Violi,et al.  Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: A meta-analysis of interventional trials. , 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[22]  J. Weitz,et al.  Evolving use of new oral anticoagulants for treatment of venous thromboembolism. , 2014, Blood.

[23]  Alexander Parkhomenko,et al.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.

[24]  E. Kuipers,et al.  New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. , 2013, Gastroenterology.

[25]  Carol Lefebvre,et al.  How to identify randomized controlled trials in MEDLINE: ten years on. , 2006, Journal of the Medical Library Association : JMLA.

[26]  H. Chew,et al.  Incidence of venous thromboembolism and its effect on survival among patients with common cancers. , 2006, Archives of internal medicine.

[27]  Paolo Prandoni,et al.  Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. , 2002, Blood.